Rapid Method Development To Overcome Challenges Of Bi-Specific Antibody Purification

Source: Lonza

By Alice Harrison, Global Technical & CMC Director for Analytics, Lonza, and Stuart Jamieson, Global Technical & CMC Director for Downstream Development, Lonza


Bi-specific antibodies (bsAbs) are becoming increasingly prevalent in the landscape of biopharmaceutical manufacturing. While bsAbs share structural similarities with monoclonal antibodies (mAbs), downstream purification faces challenges with bsAb-specific by-products such as mispaired chains, unwanted fragments, and higher aggregation levels. bsAbs present a distinct set of purification challenges due to common molecule characteristics, such as low product yields and high aggregate concentrations, that are not present in mAb processes.

In this article, Stuart Jamieson and Alice Harrison at Lonza discuss the downstream issues that development scientists encounter and the need for rapid method development.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Discovery Online